SCHEMBL18701969

SCHEMBL18701969

CC(C)(C)C(=O)N1CCN(c2nc(-c3ccc(F)nc3)cs2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
LMNA P02545 5/20 0.53
MAPK1 P28482 5/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
HTT P42858 2/20 0.53
ALDH1A1 P00352 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
SPR P35270 1/20 0.49
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
FAAH O00519 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18711775 0.87 MAPT (0.56) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702140 0.87 MAPT (0.55) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702139 0.86 MAPT (0.50) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702142 0.83 FAAH (0.61) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702144 0.83 MAPT (0.56) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702156 0.83 MAPT (0.71) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702019 0.82 RAB9A (0.57) MAPTLMNAMAPK1SMN1; SMN2HTT
SCHEMBL18702201 0.82 TP53 (0.49) MAPTSPRRAB9ANPC1TP53
SCHEMBL18702027 0.81 MAPT (0.57) MAPTLMNAMAPK1SMN1; SMN2ALDH1A1
SCHEMBL18702016 0.80 MAPT (0.53) MAPTLMNAMAPK1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963462-B2 Sepiapterin reductase inhibitors MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2018-05-08 US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS SPR, QDPR, SRR MAPT 3010/4885LMNA 4836/4885MAPK1 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.